%PDF-1.4
%
59 0 obj
<>
endobj
116 0 obj
<>/Font<>>>/Fields[]>>
endobj
56 0 obj
<>
endobj
23 1 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-05T11:15:49Z
2024-03-28T16:35:47-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:35:47-07:00
application/pdf
Heather
2001-389.jan
uuid:f97607e6-1dd1-11b2-0a00-da08277d8900
uuid:f97607e9-1dd1-11b2-0a00-d30000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
137 0 obj
[141 0 R]
endobj
138 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc -0.0139 Tw 9.7 0 0 10 54 713.1616 Tm
[(standing )54.9 (AS with a fused spine have limited benefit from such)]TJ
0.0006 Tw 0 -1.2 TD
(therapy there are phenomena that remain unexplained. One of)Tj
0.0556 Tw T*
[(our uSpA)-250.7 (patients had clear benefit for his enthesitis, but the)]TJ
0.1283 Tw T*
[(back symptoms did not improve. )17.7 (This patient had a normal)]TJ
0.0461 Tw T*
[(CRP)110.7 (. Since we have mostly treated SpA)-241.3 (patients with elevat-)]TJ
0.09801 Tw T*
[(ed CRP)-311.3 (levels, we cannot say much about those with active)]TJ
0.0507 Tw T*
[(disease and normal CRP)-263.9 (\321 who do exist in significant num-)]TJ
-0.0002 Tc 0 Tw T*
(bers)Tj
0.00079 Tc 6.3 0 0 6.5 70.1556 632.4615 Tm
(18)Tj
-0.00011 Tc 0.015 Tw 9.7 0 0 10 76.4606 629.1616 Tm
[(. However)39.7 (, with regard to the clear ef)17.7 (fects of infliximab)]TJ
0.0437 Tw -2.3155 -1.2 Td
[(on CRP)-256.9 (and interleukin 6 levels)]TJ
0.0005 Tc 0 Tw 6.3 0 0 6.5 179.4137 620.4615 Tm
(2,17)Tj
-0.00011 Tc 0.0437 Tw 9.7 0 0 10 190.4474 617.1616 Tm
(, it may be that the patient)Tj
0.0618 Tw -14.0667 -1.2 Td
[(subset with normal CRP)-275 (levels does not respond in the same)]TJ
0 Tw T*
[(way)64.8 (.)]TJ
0.0712 Tw 1.2371 -1.2 Td
[(W)79.9 (e observed no relevant side ef)17.7 (fects in the small number)]TJ
0.00369 Tw -1.2371 -1.2 Td
(of patients reported here, who were followed over a relatively)Tj
0.1088 Tw T*
(short time. In general, there is no evidence for an increased)Tj
0.0804 Tw T*
(prevalence of infections)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 148.7325 548.4615 Tm
(19)Tj
-0.00011 Tc 0.0804 Tw 9.7 0 0 10 155.0374 545.1616 Tm
[(, but, very rarely)64.8 (, cases of tubercu-)]TJ
0.0592 Tw -10.4162 -1.2 Td
(losis have been reported. Nevertheless, although there is still)Tj
0.35049 Tw T*
[(limited experience with this therapy in SpA)-545.6 (\(about 300)]TJ
0.0222 Tw T*
(patients have now been treated worldwide\), we feel the bene-)Tj
0.09129 Tw T*
[(fits of anti-TNF therapy justify a small risk. )17.7 (This discussion)]TJ
0.02499 Tw T*
(will be important to have with our patients as well. )Tj
0.0099 Tc 0.03709 Tw 1.2371 -1.2 Td
(Having tested the BASDAI in a study of sulfasalazine in)Tj
0.2206 Tw -1.2371 -1.2 Td
[(uSpA)-425.7 (\(unpublished data\), we were confident this disease)]TJ
0.1274 Tw T*
(activity index could also be used for uSpA, because the 2)Tj
0.17149 Tw T*
(main and most common symptoms of SpA, inflammatory)Tj
-0.02271 Tw T*
(back pain and peripheral arthritis of the lower limbs, are also)Tj
0.10361 Tw T*
(common in uSpA)Tj
0 Tc 0 Tw 6.3 0 0 6.5 125.8024 416.4616 Tm
(2)Tj
0.0099 Tc 0.10361 Tw 9.7 0 0 10 132.5448 413.1616 Tm
(and they are a central part of the BAS-)Tj
0 Tw -8.0974 -1.2 Td
(DAI.)Tj
-0.00011 Tc 0.01711 Tw 1.2371 -1.2 Td
[(Therapy directed against )17.8 (TNF-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.017 Tw 13.2863 0 Td
(seems to hit a critical tar-)Tj
-0.034 Tw -14.5234 -1.2 Td
(get in SpA. Further studies should clarify whether transition to)Tj
0.1274 Tw T*
(AS can be prevented by consequent antiinflammatory treat-)Tj
0.0481 Tw T*
[(ment strategies. )17.7 (The optimal dose might have to be individu-)]TJ
0.02499 Tw T*
(ally determined.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 307.1616 Tm
[(1.)-875.1 (Dougados M, van der Linden S, Juhlin R, et al. )17.7 (The European)]TJ
1.675 -1.25 Td
(Spondylarthropathy Study Group preliminary criteria of the)Tj
0 -1.25 TD
[(classification of spondyloarthropathy)64.9 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:1218-72.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Brandt J, Bollow M, H\212berle J, et al. Studying patients with)]TJ
1.675 -1.25 Td
(inflammatory back pain and arthritis of the lower limbs clinically)Tj
T*
[(and by magnetic resonance imaging: many)64.8 (, but not all patients with)]TJ
T*
[(sacroiliitis have spondyloarthropathy)64.8 (. Rheumatology 1999;)]TJ
0 Tc 0 Tw T*
(38:831-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.2375 Td
[(3.)-875.1 (Mau )17.7 (W)91.9 (, Zeidler H, Mau R, et al. Clinical features and prognosis of)]TJ
1.675 -1.2375 Td
(patients with possible ankylosing spondylitis. Results of a 10-year)Tj
0 -1.2375 TD
[(followup. J Rheumatol 1988;7:1)36.8 (109-14.)]TJ
-1.675 -1.2375 Td
[(4.)-875.1 (Dougados M, van der Linden S, Leirisalo-Repo M, et al.)]TJ
1.675 -1.2375 Td
[(Sulfasalazine in the treatment of spondylarthropathy)64.8 (. )54.8 (A)-220.1 (randomized,)]TJ
T*
[(multicenter)39.7 (, double-blind, placebo-controlled study)64.8 (. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38:618-27.)Tj
-0.00011 Tc 31.325 69.5835 Td
[(5.)-875.1 (Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in)]TJ
1.675 -1.2375 Td
(situ hybridization techniques in the examination of sacroiliac joint)Tj
T*
(biopsy specimens from patients with ankylosing spondylitis.)Tj
T*
(Arthritis Rheum 1995;38:499-505.)Tj
-1.675 -1.2375 Td
[(6.)-875.1 (Brandt J, Haibel H, Cornely D, et al. Successful treatment of active)]TJ
1.675 -1.2375 Td
(ankylosing spondylitis with the anti-tumor necrosis factor alpha)Tj
T*
[(monoclonal antibody infliximab. )54.8 (Arthritis Rheum 2000;43:1346-52.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (V)110.8 (an den Bosch F)79.7 (, Kruithof E, Baeten D, De Keyser F)79.7 (, Mielants H,)]TJ
1.675 -1.25 Td
[(V)110.8 (eys EM. Ef)17.7 (fects of a loading dose regimen of three infusions of)]TJ
0 -1.25 TD
(chimeric monoclonal antibody to tumour necrosis factor alpha)Tj
T*
[(\(infliximab\) in spondyloarthropathy: an open pilot study)64.8 (. )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 2000;59:428-33.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Mease PJ, Gof)17.7 (fe BS, Metz J, )17.7 (V)110.8 (ander Stoep )54.8 (A, Finck B, Bur)17.7 (ge DJ.)]TJ
1.675 -1.25 Td
(Etanercept in the treatment of psoriatic arthritis and psoriasis: a)Tj
T*
(randomised trial. Lancet 2000;356:385-90.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Knight DM, )17.7 (T)35 (rinh H, Le J, et al. Construction and initial)]TJ
1.675 -1.25 Td
[(characterization of a mouse-human chimeric anti-TNF antibody)64.8 (.)]TJ
T*
(Mol Immunol 1993;30:1443-53.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (V)110.8 (an der Heijde D, Bellamy N, Calin )54.8 (A, Dougados M, Khan MA,)]TJ
2.175 -1.25 Td
(van der Linden S. Preliminary core sets for endpoints in ankylosing)Tj
T*
(spondylitis. J Rheumatol 1997;24:2225-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Garrett S, Jenkinson )17.7 (TR, Kennedy LG, )17.7 (Whitelock HC, Gaisford P)110.7 (,)]TJ
2.1381 -1.25 Td
[(Calin )54.8 (A. )54.8 (A)-220.1 (new approach to defining disease status in ankylosing)]TJ
T*
[(spondylitis. )17.7 (The Bath )54.8 (AS Disease )54.8 (Activity Index. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:2286-91.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (W)79.9 (are JE Jr)39.7 (, Sherbourne CD. )17.7 (The MOS 36-item short-form health)]TJ
2.175 -1.25 Td
(survey \(SF-36\). I. Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Calin )54.8 (A, Garrett S, )17.7 (Whitelock HC, et al. )54.8 (A)-220.1 (new approach to)]TJ
2.175 -1.25 Td
[(defining functional ability in ankylosing spondylitis. )17.7 (The Bath )54.8 (AS)]TJ
T*
(Functional Index. J Rheumatol 1994;21:2286-91.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Jenkinson )17.7 (TR, Mallorie P)91.7 (A, )17.7 (Whitelock HC, Kennedy LG, Garrett S,)]TJ
2.175 -1.25 Td
[(Calin )54.8 (A. Defining spinal mobility in ankylosing spondylitis. )17.7 (The)]TJ
T*
[(Bath )54.8 (AS Metrology Index. J Rheumatol 1994;21:1694-8.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Boyer GS, Lanier )54.8 (AP)110.8 (, )17.7 (T)69.9 (emplin DW)91.7 (. Prevalence rates of)]TJ
2.175 -1.25 Td
(spondyloarthropathies, rheumatoid arthritis, and other rheumatic)Tj
T*
[(disorders in an )54.8 (Alaskan Inupiat Eskimo population. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1988;15:678-83.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Braun J, Bollow M, Remlinger G, et al. Prevalence of)]TJ
2.175 -1.25 Td
[(spondylarthropathies in HLA)-220.2 (B27-positive and -negative blood)]TJ
T*
[(donors. )54.8 (Arthritis Rheum 1998;41:58-67.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Maini R, St Clair EW)91.7 (, Breedveld F)79.7 (, et al. Infliximab \(chimeric anti-)]TJ
2.175 -1.25 Td
(tumour necrosis factor alpha monoclonal antibody\) versus placebo)Tj
T*
(in rheumatoid arthritis patients receiving concomitant methotrexate:)Tj
T*
[(a randomised phase III trial. )54.8 (A)110.8 (TTRACT)-257.3 (Study Group. Lancet)]TJ
0 Tc 0 Tw T*
(1999;354:1932-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Spoorenber)17.7 (g )54.8 (A, van der Heijde D, de Klerk E, et al. Relative value)]TJ
2.175 -1.25 Td
(of erythrocyte sedimentation rate and C-reactive protein in)Tj
T*
(assessment of disease activity in ankylosing spondylitis. )Tj
T*
(J Rheumatol 1999;26:980-4.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Gershon S, )17.7 (W)39.9 (ise RP)110.7 (, Niu M, Siegel J. Postlicensure reports of)]TJ
2.175 -1.25 Td
(infection during use of etanercept and infliximab [abstract].)Tj
T*
(Arthritis Rheum 2001;44 Suppl: 2857.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (V)110.8 (an der Linden S, )17.7 (V)110.8 (alkenbur)17.7 (g HA, Cats )54.8 (A. Evaluation of diagnostic)]TJ
2.175 -1.25 Td
(criteria for ankylosing spondylitis: a proposal for modification of)Tj
T*
[(the New )36.8 (Y)99.8 (ork criteria. )54.8 (Arthritis Rheum 1984;27:361-8.)]TJ
ET
0 0 0 0 k
440 777 117 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_3 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(122)Tj
ET
0 0 0 0 k
/GS0 gs
103.97 59.17 407.5 -10.83 re
f*
0.5 w
103.97 59.17 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
37 0 obj
<>stream
8;Z\7!KP&O#ikq,j?%SN@W2rX85r
=-/]m<-Ljj>nFjE03P[
`m_LHl+^g*;13o0(rQ[2!_3u,$a6JdQ&C)_-.a2$M]$7pYf0d84=.;a!52^@f]/_f
'FX=(nN3\K?@i<;eZ@1]3Zua##'[_s;*/#E7qNasW?PJkQs-K;g#;9gEUgiK%3W7(
)83imOX7TmO'76I;=a]`i2=W7'M#VJT&cg-Dl_b,>'#?:gIF&aFW<_Et[Q
bP9HJ`Z3[p\1>S$p@_u'_CqA:>051R);m>jIEJ/$[d8k'!ZaNXE.$*L/FR?;.,O38
ps;[,R98FnU=o"4W*@&Z>(2#EZL
<'YJWN*AK!jn[2RTtme.l3a?[\o1gR.ck1Y*.!Wni:Dp#lEh"HNj'#YcZlo:94>DD
'[?6e2jb(R_K=C8$bc;Bf3\>KP66.Yb'h4+kj
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
67 0 obj
<>
endobj
73 0 obj
<>
endobj
26 0 obj
<>
endobj
62 0 obj
<>
endobj
103 0 obj
<>
endobj
124 0 obj
<>
endobj
63 0 obj
<>
endobj
98 0 obj
<>stream
HUiPSY~GC1MxM2cmvCAPQ$BH %$D6 @6 R26+43:ChykWOSխs~|Ǭ0ǝBvݼ<%ob1gY1s&6j1bgx9('O6,6_·[ڶSg}}Wq}}72%Uk{kIDG"҅tH!Av ;AKƴ4C y9|!@x Gha:!I2ymtBFJA6ͷ ʼnB~?!W%-ͳ٘+}4b*[M`\uacaX*w8cJC%ziփӬ_mx6X;[9asF~ahχmdO.5~/jeWQvds$"^,SD#+[`%tT\WRfcTM5zzeZHUw
ނa8eIVyq*3'ioJFDӗm
Mͼ>黑FZ.jz:5no}2x/)06\6Aƞjnl/k)ȡҤIϊeyJy
{ȡ_p(&38E7_deTMQ6XzEWSQAX7ZxhsEJINUZQo2k
8\$y=] K*) @>/V+v8 ew6`qd &oLK!cT 1?FfO\[öme*cF)~D^RɺJA@aK!ĢE5-~p\6xQ3nj5qJqujx`aZ;T ln$Ep.*D
rq$LOP'|!X^ZBH}n{iOuIk $9f6;Óp|NTJ8ic݁LY=!ƥעHdž[|vUqIWҥ~qKwP`ωsRHǷ(|ky&1cDxą͊yiyұCwGE_<:~ォNф]$GbQ@=NB}ooH +ԗs,==YE/G[!s9&S(䌼W n˚ޝ>Ey|ALt5_}P+:5 aHx̬zYl;5
a7eO@,wMbhw;0iXك2aJRe,/Y!N,^qr~Dc*Kw`TX]$lA\X[~h5ֆFGxxCi}u-rK)B ?94ra
2?"
yȪ< ',G_d"u\᎒()R(s4
Zʦ1.7ٟzg3JJ{lbMM^!bvZڧM/glRs
*0oXțDbmtZoP4Ky%VʼJV$:BiqWŨ],au!TkjhP5+NJkAʑҥO]P$7
HڙICe7.f>
s@}bUaMDz